KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Merck (MRK) Current Assets (2016 - 2025)

Merck (MRK) has disclosed Current Assets for 17 consecutive years, with $43.5 billion as the latest value for Q4 2025.

  • On a quarterly basis, Current Assets rose 12.21% to $43.5 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $43.5 billion, a 12.21% increase, with the full-year FY2025 number at $43.5 billion, up 12.21% from a year prior.
  • Current Assets was $43.5 billion for Q4 2025 at Merck, down from $47.6 billion in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $47.6 billion in Q3 2025 to a low of $26.9 billion in Q1 2021.
  • A 5-year average of $34.5 billion and a median of $32.8 billion in 2023 define the central range for Current Assets.
  • Peak YoY movement for Current Assets: fell 9.95% in 2023, then grew 27.45% in 2024.
  • Merck's Current Assets stood at $30.3 billion in 2021, then increased by 18.03% to $35.7 billion in 2022, then dropped by 9.95% to $32.2 billion in 2023, then rose by 20.56% to $38.8 billion in 2024, then grew by 12.21% to $43.5 billion in 2025.
  • Per Business Quant, the three most recent readings for MRK's Current Assets are $43.5 billion (Q4 2025), $47.6 billion (Q3 2025), and $37.1 billion (Q2 2025).